Expert Interviews

Case Presentation 2: Transplant-Ineligible NDMM and Treatment With the DRd Regimen
May 24, 2022

Experts review a second patient case wherein transplant-ineligible newly diagnosed multiple myeloma was treated with the daratumumab, lenalidomide and dexamethasone regimen and how updated data from the MAIA trial can be incorporated into clinical practice.

ELEVATE-RR: Efficacy Data
May 24, 2022

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Role for Transplantation and Maintenance Therapy in NDMM
May 24, 2022

Considerations for assessing eligibility of patients for transplantation for NDMM and how maintenance therapy may be initiated in the post-transplant setting.

Patient Characteristics in ELEVATE-RR
May 24, 2022

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.

Uday R. Popat, MD, on Post-Transplant Cyclophosphamide Following Myeloablative Busulfan as GVHD Prophylaxis
May 23, 2022

Uday R. Popat, MD, spoke about how use of post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease following matched donor hematopoietic cell transplantation for acute myeloid leukemia could impact the standard of care.

Role of Neurooncologists in Management of HER2+ Breast Cancer and Brain Metastases
May 23, 2022

A look at the evolving role of neurooncologists in the treatment of patients with HER2+ breast cancer and brain metastases and future perspectives in the management of this patient population.

A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study
May 23, 2022

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.

ASCO GU 2022 Updates: Antibody-Drug Conjugates
May 23, 2022

Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.

Trastuzumab Deruxtecan Treatment for Metastatic HER2+ Breast Cancer with Brain Metastases
May 23, 2022

Experts have a conversation of the use of trastuzumab deruxtecan therapy for patients with progressive brain metastases while weighing common toxicities and clinical trial data.

ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy
May 23, 2022

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.